Capricor Therapeutics shares surged significantly after the FDA agreed to review new drug data. The company had faced setbacks last month regarding its experimental Duchenne muscular dystrophy treatment. New 24-month data will focus on improving upper limb muscle function for the drug. Analysts view the FDA’s willingness to review this information as a positive development. Capricor is pacing commercial launch spending while awaiting regulatory clarity on the drug.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.